Partnering with leading UK cancer charities to enhance patient treatment and support
Why do charities need to keep funding research into leukemia and blood cancer in general?
Novel targets for AML
The spliceosome mutations that can cause hematological malignancies
The development of novel treatment modalities: regulations and expectations